文献速递泌尿男性生殖肿瘤

骨转移负荷与前列腺放疗生存获益的关联:随机临床试验二次分析

Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2021-01-01

该研究为STAMPEDE试验M1放疗对比的探索性分析,纳入1939例新诊断转移性前列腺癌患者,评估骨转移计数和部位与前列腺放疗生存获益的关联。结果显示骨转移计数与OS和FFS获益相关,获益随骨转移数目增加而持续下降,在≤3个骨转移时最明显;低转移负荷患者(M1a或无内脏转移且≤3个骨转移)获益更大。

要点

  • 骨转移计数与前列腺放疗的OS和FFS获益相关,获益随转移数增加而下降。
  • ≤3个骨转移患者获益最明显,>3个骨转移时95%CI上限跨过等效线。
  • 低转移负荷(M1a或≤3骨转移无内脏转移)患者放疗获益显著优于高负荷患者。

核心结论

  • 基于常规影像的骨转移计数和转移部位与M1前列腺癌患者接受前列腺放疗的OS和FFS获益相关。

研究设计与样本

  • STAMPEDE试验M1放疗对比的探索性分析,纳入1939/2061例新诊断转移性前列腺癌患者,中位年龄68岁,89%有骨转移。
  • 患者随机接受标准治疗(ADT±多西他赛)或标准治疗联合前列腺放疗。
  • 采用多变量分数多项式交互过程评估基线骨转移计数与OS和FFS的关联,并进行亚组分析。

主要发现

  • 骨转移计数与前列腺放疗的OS和FFS获益相关,生存获益随骨转移数目增加而持续下降,≤3个骨转移时获益最明显。
  • 估计疗效图显示>3个骨转移时95%CI上限跨过等效线(HR=1),未检测到变化点。
  • 低转移负荷组(仅非区域淋巴结M1a或≤3个骨转移无内脏转移)OS的HR为0.62(95%CI 0.46-0.83),FFS的HR为0.57(95%CI 0.47-0.70)。

临床怎么用

  • 对于新诊断M1前列腺癌患者,可依据常规影像评估骨转移计数和部位来筛选前列腺放疗的潜在获益人群。
  • 低转移负荷(M1a或≤3个骨转移无内脏转移)患者更可能从前列腺放疗中获得OS和FFS获益。

局限性

  • 本研究为探索性分析,结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Prostate radiotherapy (RT) improves survival in men with low-burden metastatic prostate cancer. However, owing to the dichotomized nature of metastatic burden criteria, it is not clear how this benefit varies with bone metastasis counts and metastatic site. OBJECTIVE: To evaluate the association of bone metastasis count and location with survival benefit from prostate RT. DESIGN, SETTING, AND PARTICIPANTS: This exploratory analysis of treatment outcomes based on metastatic site and extent as determined by conventional imaging (computed tomography/magnetic resonance imaging and bone scan) evaluated patients with newly diagnosed metastatic prostate cancer randomized within the STAMPEDE trial's metastasis M1 RT comparison. The association of baseline bone metastasis counts with overall survival (OS) and failure-free survival (FFS) was assessed using a multivariable fractional polynomial interaction procedure. Further analysis was conducted in subgroups. INTERVENTIONS: Patients were randomized to receive either standard of care (androgen deprivation therapy with or without docetaxel) or standard of care and prostate RT. MAIN OUTCOMES AND MEASURES: The primary outcomes were OS and FFS. RESULTS: A total of 1939 of 2061 men were included (median [interquartile range] age, 68 [63-73] years); 1732 (89%) had bone metastases. Bone metastasis counts were associated with OS and FFS benefit from prostate RT. Survival benefit decreased continuously as the number of bone metastases increased, with benefit most pronounced up to 3 bone metastases. A plot of estimated treatment effect indicated that the upper 95% CI crossed the line of equivalence (hazard ratio [HR], 1) above 3 bone metastases without a detectable change point. Further analysis based on subgroups showed that the magnitude of benefit from the addition of prostate RT was greater in patients with low metastatic burden with only nonregional lymph nodes (M1a) or 3 or fewer bone metastases without visceral metastasis (HR for OS, 0.62; 95% CI, 0.46-0.83; HR for FFS, 0.57; 95% CI, 0.47-0.70) than among patients with 4 or more bone metastases or any visceral/other metastasis (HR for OS, 1.08; 95% CI, 0.91-1.28; interaction P = .003; HR for FFS, 0.87; 95% CI, 0.76-0.99; interaction P = .002). CONCLUSIONS AND RELEVANCE: In this exploratory analysis of a randomized clinical trial, bone metastasis count and metastasis location based on conventional imaging were associated with OS and FFS benefit from prostate RT in M1 disease. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00268476; ISRCTN.com Identifier: ISRCTN78818544.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Ali A, Hoyle A, Haran ÁM, et al. Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2021. PMID: 33599706. doi:10.1001/jamaoncol.2020.7857

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。